Project title
卵巢透明細胞癌 (OCCC) 中的融合基因-卵巢亮細胞癌（OCCC）融合轉錄本（FTs）作為治療靶點的發現、特徵化與驗證 (I)
Internal ID
NSTC114-2314-B002-250
Principal Investigator
Start Date
August 1, 2025
End Date
July 31, 2026
Investigators
Organizations
Partner Organizations
Discovery, Characterization, and Validation of Fusion Transcripts (Fts) as Therapeutic Targets in Ovarian Clear Cell Carcinoma (Occc) (I) = 卵巢透明細胞癌 (OCCC) 中的融合基因-卵巢亮細胞癌（OCCC）融合轉錄本（FTs）作為治療靶點的發現、特徵化與驗證 (I)
Keywords
Ovarian clear cell carcinoma (OCCC)
fusion transcripts（FTs）
Description
Academic Development: Elucidating the molecular mechanisms of fusion transcripts in OCCC, addressing research gaps in gynecologic oncology, and establishing a multidisciplinary research framework to advance precision medicine's foundational and translational studies. Clinical Applications: Identifying and testing targeted therapies such as MET inhibitors to provide personalized treatment options for recurrent OCCC patients with in-frame MET fusion, ultimately improving clinical outcomes. Social and Economic Impact: Enhancing patient prognosis, reducing the healthcare burden associated with chemoresistance, and driving innovation in cancer therapy while solidifying Taiwan's leadership in gynecologic oncology research. The ultimate goal of this project is to establish a clinical diagnostic and therapeutic framework for fusion transcripts, providing a robust scientific and clinical foundation for precision medicine in OCCC